--- title: "Yili Chuanning Bio has been approved to register 1 billion yuan medium-term notes" type: "News" locale: "en" url: "https://longbridge.com/en/news/257024472.md" description: "According to the Zhitong Finance APP, Yili Chuanning Bio announced that the company has received the \"Acceptance of Registration Notice\" issued by the Association of Dealers. The Association of Dealers has agreed to accept the registration of the company's medium-term notes, with a registered amount of 1 billion yuan. The registration quota is valid for 2 years from the date of this notice" datetime: "2025-09-12T03:54:05.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/257024472.md) - [en](https://longbridge.com/en/news/257024472.md) - [zh-HK](https://longbridge.com/zh-HK/news/257024472.md) generator: "portal-rs" --- # Yili Chuanning Bio has been approved to register 1 billion yuan medium-term notes According to the Zhitong Finance APP, Yili Chuanning Bio (301301.SZ) announced that the company has received the "Acceptance of Registration Notice" issued by the Association of Dealers, which agrees to accept the registration of the company's medium-term notes with a registration amount of 1 billion yuan. The registration quota is valid for 2 years from the date of this notice ### Related Stocks - [301301.CN](https://longbridge.com/en/quote/301301.CN.md) ## Related News & Research - [Livzon Pharma buys 3.5% Xinbeijiang Pharma stake for RMB 106.7 million](https://longbridge.com/en/news/296601614.md) - [Promise Analyzes Telehealth Licensing Rules as Compact Hits Record 3,633 Licenses in a Month](https://longbridge.com/en/news/296635882.md) - [Elon Musk Agrees With Grok's Critics—Says a Fix Is Coming](https://longbridge.com/en/news/296618923.md) - [giga! Equips All Eligible MILK Fund Scholars with One-year gigaFLEX+ Plan](https://longbridge.com/en/news/296587727.md) - [SandboxAQ introduces AQPotency for virtual drug screening](https://longbridge.com/en/news/296467103.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**